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Abstract
Purpose: The purpose of the current study was threefold: (a) investigate the impact
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of the variations (errors) in spot sizes in robustly optimized pencil beam scanning
(PBS) proton-based stereotactic body radiation therapy (SBRT) lung plans, (b) evaluate the impact of spot sizes and position errors simultaneously, and (c) assess the
overall effect of spot size and position errors occurring simultaneously in conjunction with either setup or range errors.
Methods: In this retrospective study, computed tomography (CT) data set of ﬁve
lung patients was selected. Treatment plans were regenerated for a total dose of
5000 cGy(RBE) in 5 fractions using a single-ﬁeld optimization (SFO) technique.
Monte Carlo was used for the plan optimization and ﬁnal dose calculations. Nominal
plans were normalized such that 99% of the clinical target volume (CTV) received
the prescription dose. The analysis was divided into three groups. Group 1: The
increasing and decreasing spot sizes were evaluated for 10%, 15%, and 20%
errors. Group 2: Errors in spot size and spot positions were evaluated simultaneously
(spot size: 10%; spot position: 1 and 2 mm). Group 3: Simulated plans from
Group 2 were evaluated for the setup (5 mm) and range (3.5%) errors.
Results: Group 1: For the spot size errors of 10%, the average reduction in D99%
for −10% and +10% errors was 0.7% and 1.1%, respectively. For −15% and +15%
spot size errors, the average reduction in D99% was 1.4% and 1.9%, respectively.
The average reduction in D99% was 2.1% for −20% error and 2.8% for +20% error.
The hot spot evaluation showed that, for the same magnitude of error, the decreasing spot sizes resulted in a positive difference (hotter plan) when compared with the
increasing spot sizes. Group 2: For a 10% increase in spot size in conjunction with a
−1 mm (+1 mm) shift in spot position, the average reduction in D99% was 1.5%
(1.8%). For a 10% decrease in spot size in conjunction with a −1 mm (+1 mm) shift
in spot position, the reduction in D99% was 0.8% (0.9%). For the spot size errors of
10% and spot position errors of 2 mm, the average reduction in D99% was 2.4%.
Group 3: Based on the results from 160 plans (4 plans for spot size [10%] and
position [1 mm] errors × 8 scenarios × 5 patients), the average D99% was
4748 cGy(RBE) with the average reduction of 5.0%. The isocentric shift in the
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superior–inferior direction yielded the least homogenous dose distributions inside
the target volume.
Conclusion: The increasing spot sizes resulted in decreased target coverage and
dose homogeneity. Similarly, the decreasing spot sizes led to a loss of target coverage, overdosage, and degradation of dose homogeneity. The addition of spot size
and position errors to plan robustness parameters (setup and range uncertainties)
increased the target coverage loss and decreased the dose homogeneity.
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1 | INTRODUCTION

Previous publications1-9 have reported the variations in spot size
and position in the phantoms and disease sites but not for the lung. For

In pencil beam scanning (PBS) proton delivery, the accuracy of the

PBS lung cancer treatment, the accuracy of the dose calculation algo-

size and position of a pencil proton beam is very critical to minimize

rithm in predicting spot size and dose distributions becomes more criti-

the discrepancies between the delivered and computed doses. Spot

cal due to varying tissue densities in the proton beam path. In

sizes on the proton beam delivery system can be affected by the

commercial proton treatment planning systems (TPS), Monte Carlo algo-

ﬂuctuations in the beam extraction and transport systems.1 Addition-

rithms have been shown to be more accurate in estimating spot sizes

ally, the presence of different scattering materials in the nozzle,1 as

than analytical pencil beam algorithms.12,13 A growing number of publi-

well as the air gap between the range shifter and patient, can have

cations14–17 have now recommended using the Monte Carlo algorithm

2

an impact on the spot size. Similarly, the positioning of the spots

for the dose calculations in PBS lung cancer. Recently, robust optimiza-

can be affected by the ﬂuctuations in the steering magnetic ﬁelds.3,4

tion14,18 feature has been made available in the clinical environment,

Hence, the variations in the delivered spot sizes and positions could

whereas previous studies1,5-8 did not address the impact of variation in

lead to perturbation of dose distributions impacting the quality of

spot size on robustly optimized clinical plans. It is essential to under-

the treatment plan delivered to the patient.1–7

stand the effects of errors in spot sizes on the Monte Carlo algorithm-

In order to minimize the discrepancies between the computed

based robustly optimized PBS lung cancer plans. Additionally, none of

and delivered dose distributions in PBS proton therapy, tolerance

the previous studies1–9 have studied the impact of the errors in spot

levels are proposed for the spot size and position errors. Parodi

sizes and positions simultaneously. In the current study, we aim to

et al.1 evaluated the impact of spot size on spherical phantom plans

answer the following questions regarding the robustly optimized PBS

and proposed the tolerance of 50%. Chanrion et al.5 studied the

proton-based stereotactic body radiation therapy (SBRT) lung plans:

variations in spot sizes on prostate and skull-base patients and
reported negligible to moderate changes in dose distributions when
spot sizes are changed by ⩽25%. Lin et al.8 performed a study on
28 patients of different disease sites (breast, sarcoma, central nervous system, pediatric, gastrointestinal, genitourinary, and gynecological). Based on their gamma analysis, the spot size tolerance of
10% was proposed.8 Kraan and colleagues7 demonstrated that the
variation in spot size is patient and spot width dependent. Their
study7 included seven patients of different disease sites (pelvis,
chest wall, rectum, chordoma, cardiac, retro-peritoneal, and sarcoma)

1. What is the dosimetric impact of spot size errors of 10%,
15%, and 20%?
2. What is the dosimetric impact of spot size and position errors
occurring simultaneously? The simultaneous evaluation is performed by combining spot size and position errors (spot size:
10% and spot position: 1 and 2 mm)?
3. What are the overall effect of spot size (10%) and position
(1 mm) errors in conjunction with either setup (5 mm) or
range (3.5%) errors?

and a phantom. If in-air one sigma (σ) of a pencil beam is 2.5 mm,
the tolerance is 25%.7 Similarly, for σ of 5 and 10 mm, the pro-

2 | MATERIALS AND METHODS

posed tolerances are 25% and 10%, respectively.7 For the spot
position errors, the tolerance of 1 mm has been reported by the
investigators.4,8–10 Recently, the AAPM TG224 report11 recommended the tolerance of 10% for the spot size and 1 mm for
the spot position.

2.A | Contouring and treatment planning
In this retrospective study, PBS lung plans were replanned on the
computed tomography (CT) data set of ﬁve lung patients. The

|
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clinical target volume (CTV) ranged from 24.27 to 63.24 cc. The

thus resulting in two simulated plans, D(0%, −1 mm) and D(0%,

CTV was created by an isotropic margin of 5 mm around

+1 mm), respectively. This process was repeated for the systematic

the internal gross tumor volume (IGTV). The IGTV was obtained

shift of spot positions by 2 mm to generate D(0%, −2 mm) and D

based on the four-dimensional computed tomography (4DCT)

(0%, +2 mm) plans. The simulation of spot position errors was per-

images. For proton planning, the average intensity projection CT

formed using an in-house developed MatLab code (Version R2019b;

was utilized.

MathWorks, Natick, MA, USA).

RayStation TPS (Version 9B; RaySearch Laboratories, Stockholm,
Sweden) was used for treatment planning. The proton beam model
is based on the IBA ProteusPLUS proton therapy system with a
PBS dedicated nozzle (Ion Beam Applications, Louvain-la-Neuve,
Belgium).19,20 The in-air one sigma (σ) for 226.5 MeV at the isocenter is ~3 mm.

19

2.E | Dose calculation for the spot size and position
errors occurring simultaneously
For each patient, simulated plans for spot positions (as described in

For each patient, a nominal plan was regenerated

Section 2D) were imported back into RayStation TPS. The D(0%,

for a total dose of 5000 cGy(RBE) in 5 fractions using an average

−1 mm) plan was recomputed using Monte Carlo algorithm (without

RBE of 1.1. Treatment plans were robustly optimized using a

reoptimization) for the spot size errors of −10% and +10%, resulting

single-ﬁeld optimization (SFO) technique. The Monte Carlo algo-

in D(−10%, −1 mm) and D(+10%, −1 mm) plans, respectively. The D

rithm (10 000 ions/spot) was utilized for the robust optimization.

(0%, +1 mm) plan was recomputed using Monte Carlo algorithm

The robustness (range uncertainty = 3.5% and setup error =

(without reoptimization) for the spot size errors of −10% and +10%,

5 mm) was applied on the CTV such that its 99% of the relative

resulting in D(−10%, +1 mm) and D(+10%, +1 mm) plans, respec-

volume receives at least the prescription dose (5000 cGy(RBE)).

tively. Similarly, the D(0%, −2 mm) and D(0%, +2 mm) plans were

Based on the input values of robustness parameters, RayStation

recomputed using Monte Carlo algorithm (without reoptimization)

optimized each plan for a total of 21 scenarios. The ﬁnal dose cal-

for 10% spot size errors.

culations were performed using the Monte Carlo (grid size: 2 mm;
statistical uncertainty = 0.5%). This was followed by the creation of
a volumetric repainting plan with ﬁve paintings in an alternating

2.F | Robustness

order.21,22 The resulting plan was then normalized such that the

The D(10%, 1 mm) plans were evaluated for a total of eight sce-

CTV D99% = 5000 cGy(RBE). The ﬁnal nominal plan was denoted

narios. The setup uncertainty was simulated by a 5-mm isocenter

as D(0%, 0 mm), which means 0% error in spot size and 0-mm

shift in the left–right, superior–inferior, and anterior–posterior direc-

error in spot position.

tions of the patient resulting in six scenarios. The range uncertainty
was evaluated for two scenarios (3.5%).

2.B | Spot size errors simulation
In order to simulate the spot size errors of 10%, 15%, and 20%,

2.G | Analysis

additional six beam models were generated. These were simulated

The analysis was divided into three groups. The ﬁrst group (Group 1)

by scaling the spot proﬁles in the nominal beam model. In the simu-

consisted of plans simulated for spot size errors only, as described in

lated beam models, absolute dose output and integrated depth doses

Section 2.C. The second group (Group 2) included the plans that

(IDDs) remained identical as in the nominal beam model.

were simulated for spot size and position errors occurring simultaneously. The simulated plans in the Group 2 are described in Sec-

2.C | Dose calculations for spot size errors only
The spot size errors calculation was performed by recomputing D
(0%, 0 mm) plan using the simulated beam models (10%, 15%,
and 20%). For instance, if D(0%, 0 mm) plan was recomputed for

tion 2.E. Finally, the third group (Group 3) included the evaluation of
D(10%, 1 mm) plans for setup (5 mm) and range (3.5%) uncertainties as described in Section 2.F.
The difference (Δ) at a dosimetric metric (e.g., D99%) between
simulated and nominal plans was calculated using Eq. (1).

the spot size error of +10% and spot position error of 0 mm, the
resulting plan was denoted as D(+10%, 0 mm). Similarly, for −20%
spot size and 0-mm spot position errors, the plan was denoted as
D(−20%, 0 mm). Dose recomputations were performed using the
Monte Carlo algorithm without plan reoptimization.

Δ¼



DSimulated
 DNominal
x%
x%
DNominal
x%

 100

(1)

= result for x metric (e.g., 99) in the nominal plan.
DNominal
x%
= result for x metric in a simulated plan.
DSimulated
x%
The difference was averaged (Δavg) over ﬁve patients.

2.D | Spot position errors simulation

1
Δi
Δavg: ¼ ∑n¼5
5 i¼1

The D(0%, 0 mm) plan containing the spot position information was
exported from the TPS to a local computer. Then spot positions in
the treatment plan were varied systematically by −1 and +1 mm,

(2)

The CTV dose homogeneity index (HI) was evaluated using Eq.
(3), as shown below:

4
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F I G . 1 . The average difference in clinical target volume D95% (left panel) and D99% (right panel) between simulated plans in Group 1 and
nominal plans for the spot size errors (10%, 15%, and 20%). The results are averaged over all ﬁve patients.

F I G . 2 . Dose distributions in an example
patient: (a) nominal plan, (b) simulated plan
for the decreasing spot size (−10%) and
spot position (+1 mm) evaluated
simultaneously; (c) simulated plan for the
increasing spot size (+10%) and spot
position (+1 mm) evaluated simultaneously.
The loss of target coverage in the
simulated plans is shown by the red
arrows on the right panel.
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HI ¼

ðD1%  D99% Þ
Rx

5

worse for D(−20%, 0 mm) plan (0.04) than D(+20%, 0 mm) plan (0.02)
(3)

when their results were compared against D(0%, 0 mm) plan.

where Rx is the prescription dose (5000 cGy(RBE)). Based on Eq. (3),
the HI value of 0 is considered an ideal HI result.

3.B | Group 2: Spot size and position errors
occurring simultaneously

3 | RESULTS

Figure 2 illustrates the dose distributions in an example patient for
the nominal plan and simulated plan for the combined errors of the

3.A | Group 1: Spot size errors
The spot size errors resulted in a loss of the target coverage (Fig. 1).
The reduction in target coverage increased as the magnitude of spot
size error was increased.
D95%: The Δavg. at D95% for −10% and +10% errors were −0.4%
and −0.6%, respectively. The Δavg. at D95% was −1.0% for 15%
errors. The Δavg. at D95% was −1.6% for 20% errors.
D99%: The Δavg. at D99% for −10% and +10% errors were −0.7%
and −1.1%, respectively. The Δavg. at D99% was −1.4% for −15%
error and −1.9% for +15% error. The Δavg. at D99% was −2.1% for
−20% error and −2.8% for +20% error.
HI: On average, the difference in HI results between nominal D(0%,

decreasing (increasing) spot size −10% (+10%) and spot position
(+1 mm). Figure 3 shows the reduction in target coverage between
the nominal plan and simulated plan for the spot size errors (10%)
and spot position errors (1 mm). For a 10% increase in spot size
and 1-mm shift in spot position, the Δavg. at D99% was −1.5% for
D(+10%, −1 mm) plan and −1.8% for D(+10%, +1 mm) plan. For a
10% decrease in spot size and 1-mm shift in spot position, the
Δavg. at D99% was −0.8% for D(−10%, −1 mm) plan and −0.9% for D
(−10%, +1 mm) plan. Figure 3 also exhibits the results from D(10%,
2 mm) plans (n = 20) for the spot size errors of 10% and spot
position errors of 2 mm. For D(10%, 2 mm) plans, the Δavg. at
D99% was −2.4%.

0 mm) and simulated plans for 10% errors (D(+10%, 0 mm) and D
(−10%, 0 mm)) was 0.01. For 15% and 20% spot size errors, decreas-

3.C | Group 3: Setup and range errors

ing spot sizes resulted in less homogeneous plans compared with
increasing spot sizes. Speciﬁcally, for the spot size errors of 15%, it
was found that the average difference in HI was worse for D(−15%,
0 mm) plan (0.03) than D(+15%, 0 mm) plan (0.01) when their results
were compared against D(0%, 0 mm) plan. A similar trend was observed
for the spot size errors of 20%, with the average difference in HI being

Figure 4 shows the results for simulated plans when setup (six scenarios) and range (two scenarios) errors are evaluated in conjunction
with spot size (10%) and position (1 mm) errors occurring simultaneously. The results are based on 160 plans (4 plans for spot size
[10%] and position [1 mm] errors × 8 scenarios × 5 patients).

F I G . 3 . The average difference in clinical target volume D99% between simulated plans in Group 2 and nominal plans for the spot size errors
(10%) in conjunction with spot position errors (1 and 2 mm). The results are averaged over all ﬁve patients.

6
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F I G . 4 . (left panel) The average clinical target volume (CTV) D99% (left panel) from 120 plans of ﬁve patients from Group 3 analysis. (right
panel) The average difference in CTV D99% between simulated plans in Group 3 and nominal plans. The results are averaged over all ﬁve
patients.

The average D99% was 4748 cGy(RBE), with an average reduction of

current study complement previous ﬁndings1,5,7,8 by adding the

5.0%.

impact of variations in spot sizes and positions in robustly optimized

Figure 5 illustrates the difference in HI for various scenarios. The

PBS lung plans. Due to the availability of the Monte Carlo algorithm

worse HI result was obtained for a 5-mm isocenter shift in the supe-

in commercially available TPS, researchers are recommending the

rior–inferior directions (y =  5 mm). The average difference in HI

Monte Carlo algorithm for the optimization and dose calculations in

was 0.06.

the proton lung plans.14–17 The current study provides additional
information regarding the impact of spot size and position errors on
the dose distributions of the lung plans, which were robustly opti-

4 | DISCUSSION

mized (SFO technique) and calculated using the Monte Carlo algorithm.

The current study was performed to investigate the dosimetric

For a patient cohort in the current study, the variations in

impact of variations (errors) in the spot sizes and spot positions in

spot sizes resulted in decreased target coverage and dose homo-

PBS proton-based SBRT lung plans. The results reported in the

geneity. This was true for both the increasing and decreasing spot

F I G . 5 . (left panel) The difference in clinical target volume homogeneity index (HI) for eight different scenarios between simulated plans in
Group 3 and nominal plans. (right panel) Robustness parameters for eight scenarios of Group 3 analysis. The D(10%, 1 mm) plans are
evaluated for setup (5 mm) and range (3.5%) uncertainties as described in Section 2.F.
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sizes. For the spot size errors of 10%, the average loss of target

7

errors in conjunction with the spot size and spot position errors, we

coverage was almost identical. Also, there was a minimum differ-

noticed that the average decrease in D99% was by 2.0%. These

ence in the loss of target coverage between the increasing and

results suggest that the impact of setup errors was greater by three-

decreasing spot sizes for the 15% category. However, for the

fold than the impact of range errors in robustly optimized PBS lung

spot size errors of 20%, it was found that the increasing spot

plans when spot size and position errors are included in plan robust-

sizes resulted in a greater loss of target coverage at D99% when

ness evaluation. The spot size and position errors in our study were

compared with the decreasing spot sizes. The loss of target cover-

simulated systematically. During a real clinical scenario of proton

age due to the increasing and decreasing spot sizes can be attrib-

beam delivery, the deviations in spot size and position may not be

uted to the change in the lateral penumbra. The increase in spot

systematic. Future studies should investigate the impact of random

size led to the broadening of the lateral penumbra, whereas the

occurrence of spot size and position errors in PBS lung cancer plans.

decrease in spot sizes led to the contraction of the lateral penumbra.5,7 The evaluation at D1% showed that, for the same magnitude of error, the average difference was higher (positive

5 | CONCLUSION

difference) for the decreasing spot sizes than for the increasing
spot sizes. These ﬁndings suggest that the decreasing spot sizes

The increasing spot sizes resulted in decreased target coverage and

will also result in overdosage and loss dose homogeneity in the

dose homogeneity. Similarly, the decreasing spot sizes led to a loss

target volume.

of target coverage, overdosage, and degradation of dose homogene-

During proton beam delivery, there is a probability of variations

ity. The addition of spot size and position errors to plan robustness

in both spot sizes and positions. Previous studies1–9 did not investi-

parameters (setup and range uncertainties) increased the target cov-

gate the variations in spot sizes and positions simultaneously but

erage loss and decreased the dose homogeneity.

rather focused either on the spot sizes or spot positions. According
to AAPM TG224, the recommended tolerances for the spot sizes
and spot positions are 10% and 1 mm, respectively. By simulat-
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demonstrated the need for having stringent quality assurance (QA)
tolerances to avoid the loss of target coverage due to variations in
spot sizes and positions. It is important to note that clinical outcomes can be correlated to the minimum dose to the delivered
tumor volume.23,24 In a more recent study, Sood et al.24 noted the
D99% as a potential predictive parameter for clinical outcome in
photon-based lung SBRT.
The majority of the proton centers evaluate the robustness of
PBS plans against the setup and range uncertainties,25 but there
appears to be no common consensus on the plan robustness criteria
in the proton therapy community. During PBS proton beam delivery,
there is a possibility of delivered spots deviating from their calculated sizes and positions. In the current study, we demonstrated
how the variations in spot sizes and positions could be combined
with either setup uncertainty or range uncertainty. By assuming the
spot size and position errors (10% and 1 mm, respectively) occurring simultaneously in conjunction with setup errors, the D99% was
decreased by the average difference of 6.1%. Similarly, for the range
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23. Tomé WA, Fowler JF. On cold spots in tumor subvolumes. Med
Phys. 2002;29:1590–1598.
24. Sood SS, Pokhrel D, Badkul R, et al. Correlation of clinical outcome,
radiobiological modeling of tumor control, normal tissue complication
probability in lung cancer patients treated with SBRT using Monte
Carlo calculation algorithm. J Appl Clin Med Phys. 2020;21:56–62.
25. Yock AD, Mohan R, Flampouri S, et al. Robustness analysis for external beam radiation therapy treatment plans: describing uncertainty
scenarios and reporting their dosimetric consequences. Pract Radiat
Oncol. 2019;9:200–207.

